文献速递小儿眼科与斜弱视

阿托品联合遮盖与单纯遮盖治疗儿童重度弱视的随机临床试验

Effect of Combined Atropine and Patching vs Patching Alone for Treatment of Severe Amblyopia in Children Aged 3 to 12 Years: A Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

这项单中心随机临床试验纳入108名3至12岁重度弱视(20/100至20/500)儿童,比较阿托品联合遮盖(CAPT)与单纯遮盖治疗6个月的疗效。

要点

  • CAPT组6个月弱视眼视力改善较单纯遮盖组多0.14 logMAR(约1.4行)。
  • 3个月时CAPT组改善亦优于单纯遮盖组,差异0.13 logMAR。
  • 试验未发现因不良事件退出的参与者。

核心结论

  • 在3至12岁重度弱视儿童中,阿托品联合遮盖治疗6个月后弱视眼视力平均改善优于单纯遮盖,但该差异的临床意义尚不能确定。

研究设计与样本

  • 共纳入108名3至12岁重度弱视(20/100至20/500)儿童,由斜视、屈光参差或两者引起;53名随机分配至CAPT组,55名至单纯遮盖组。
  • 平均(SD)年龄5.2(1.8)岁,54名(50%)为女性。

主要发现

  • 6个月时CAPT组弱视眼视力平均改善0.72 logMAR(7.2行),单纯遮盖组为0.58 logMAR(5.8行)。
  • 基线时弱视眼平均(SD)视力为0.95(0.22)logMAR(约20/200)。
  • 无参与者因不良反应退出。

关键数值与推荐

  • 重度弱视定义为弱视眼视力20/100至20/500。
  • 主要结局为弱视眼视力从基线至6个月的变化。
  • 干预疗程为6个月。

临床怎么用

  • 对重度弱视儿童,可考虑阿托品联合遮盖以争取额外视力改善。
  • 联合方案在本试验中未出现因不良反应退出的情况。
  • 视力差异较小,是否具有临床意义需结合个体情况判断。

局限性

  • 为单中心研究,结论外推需谨慎。
  • 作者指出该视力差异的临床相关性无法从本试验确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patching is often less effective for severe amblyopia because of poor adherence. For the treatment of severe amblyopia, although combined atropine and patching therapy (CAPT) has been found to be efficacious, it is currently unknown whether CAPT is more efficacious than patching alone. OBJECTIVE: To compare the efficacy of CAPT vs patching alone in children aged 3 to 12 years with severe amblyopia. DESIGN, SETTING, AND PARTICIPANTS: This single-center randomized clinical trial was conducted from November 2018 to May 2020. The visual acuity (VA) examiner was masked to the treatment groups. The follow-up visits were at 3 months and 6 months. Participants aged 3 to 12 years with severe amblyopia (20/100 to 20/500) resulting from strabismus, anisometropia, or both were randomly assigned to CAPT or patching therapy. INTERVENTIONS: CAPT or patching alone for 6 months. MAIN OUTCOMES AND MEASURES: Change of the amblyopic eye VA from baseline to 6 months. RESULTS: Among 108 participants, the mean (SD) age was 5.2 (1.8) years, and 54 (50%) were female. Overall, 53 participants (49%) were randomized to CAPT and 55 (51%) were randomized to patching therapy. At baseline, the mean (SD) amblyopic eye VA was 0.95 (0.22) logMAR (approximately 20/200 [2.2 lines]). At 6 months, the CAPT group's mean improvement in amblyopic eye VA was 0.72 logMAR (7.2 lines) compared with 0.58 logMAR (5.8 lines) in the patching alone group (difference, 0.14 logMAR [1.4 lines] greater in the CAPT group; 95% CI, 0.05-0.22 logMAR [0.5-2.2 lines]; P = .002). The amblyopic eye VA improvement in the CAPT group also was greater than that in the patching alone group at 3 months (difference in the means, 0.13 logMAR [1.3 lines]; 95% CI, 0.04-0.22 logMAR [0.4-2.2 lines]; P = .004). No participants were withdrawn because of adverse effects. CONCLUSIONS AND RELEVANCE: CAPT resulted in more mean improvement of amblyopic eye VA than patching alone among participants enrolled in this trial, although the clinical relevance of this relatively small VA difference cannot be determined from this trial. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR1800018663.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wang S, Wen W, Zhu W, et al. Effect of Combined Atropine and Patching vs Patching Alone for Treatment of Severe Amblyopia in Children Aged 3 to 12 Years: A Randomized Clinical Trial. JAMA Ophthalmol. 2021. PMID: 34264296. doi:10.1001/jamaophthalmol.2021.2413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。